Back to top
more

Travere Therapeutics (TVTX)

(Delayed Data from NSDQ)

$5.26 USD

5.26
1,220,072

-0.13 (-2.41%)

Updated Apr 26, 2024 04:00 PM ET

After-Market: $5.25 -0.01 (-0.19%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

5-Strong Sell of 5         5

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value F Growth A Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 30% (75 out of 252)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Travere (TVTX) Q4 Earnings: How Key Metrics Compare to Wall Street Estimates

by Zacks Equity Research

While the top- and bottom-line numbers for Travere (TVTX) give a sense of how the business performed in the quarter ended December 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Axsome Therapeutics (AXSM) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

by Zacks Equity Research

Axsome (AXSM) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Travere (TVTX) Stock Up More Than 30% in 3 Months: Here's Why

by Zacks Equity Research

Travere (TVTX) is on track to file an sNDA to the FDA to convert the accelerated approval for lead drug, Filspari, to full approval for IgAN in first-quarter 2024.

Wall Street Analysts Think Travere (TVTX) Could Surge 66.29%: Read This Before Placing a Bet

by Zacks Equity Research

The consensus price target hints at a 66.3% upside potential for Travere (TVTX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Mirum (MIRM) Down on Failure of Mid-Stage Study on Livmarli

by Zacks Equity Research

Mirum (MIRM) faces a setback in its efforts to expand its lead drug Livmarli's label for the indication of biliary atresia in patients who have undergone a Kasai surgery.

Travere (TVTX) Up on Latest Portfolio Updates & Reorganization

by Zacks Equity Research

Travere (TVTX) to submit an sNDA to the FDA to convert the accelerated approval for Filspari to full approval for IgAN in first-quarter 2024. The company is implementing a strategic reorganization to cut costs. Stock rises.

Travere (TVTX) Q3 Earnings: How Key Metrics Compare to Wall Street Estimates

by Zacks Equity Research

The headline numbers for Travere (TVTX) give insight into how the company performed in the quarter ended September 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Will Intercept Pharmaceuticals (ICPT) Report Negative Q3 Earnings? What You Should Know

by Zacks Equity Research

Intercept (ICPT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Analysts Estimate Travere Therapeutics (TVTX) to Report a Decline in Earnings: What to Look Out for

by Zacks Equity Research

Travere (TVTX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Travere (TVTX) Slumps 41% on Mixed Results From IgAN Drug Study

by Zacks Equity Research

Data from a confirmatory study shows that Travere's (TVTX) IgAN therapy did not achieve one of its confirmatory secondary endpoints. This will likely hurt the company's chances for the drug's full approval.

Xoma (XOMA) Moves 7.7% Higher: Will This Strength Last?

by Zacks Equity Research

Xoma (XOMA) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Mirum Pharma (MIRM) Stock Rises 42% Year to Date: Here's Why

by Zacks Equity Research

Mirum Pharma (MIRM) surges 42% year to date due to encouraging progress in label-expansion efforts of Livmarli, along with strategic initiatives, to expand its commercial portfolio.

Travere (TVTX) Q2 Earnings: How Key Metrics Compare to Wall Street Estimates

by Zacks Equity Research

Although the revenue and EPS for Travere (TVTX) give a sense of how its business performed in the quarter ended June 2023, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Travere Therapeutics (TVTX) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

Travere (TVTX) delivered earnings and revenue surprises of 2.59% and 10.70%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Ligand (LGND) Up 3% on Raised '23 View, Beats on Q1 Earnings

by Zacks Equity Research

Ligand Pharmaceuticals (LGND) announces better-than-expected results in first-quarter 2023. Management raises 2023 financial outlook.

Travere Therapeutics (TVTX) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

Travere (TVTX) delivered earnings and revenue surprises of -7.63% and 11.90%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Techne (TECH) Meets Q3 Earnings Estimates

by Zacks Equity Research

Techne (TECH) delivered earnings and revenue surprises of 0% and 0.74%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Will Amicus Therapeutics (FOLD) Report Negative Q1 Earnings? What You Should Know

by Zacks Equity Research

Amicus Therapeutics (FOLD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Travere Therapeutics (TVTX) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

by Zacks Equity Research

Travere (TVTX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Bristol Myers Squibb (BMY) Surpasses Q1 Earnings Estimates

by Zacks Equity Research

Bristol Myers (BMY) delivered earnings and revenue surprises of 3.54% and 2.33%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Travere Therapeutics (TVTX) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research

Travere (TVTX) delivered earnings and revenue surprises of 0.96% and 1.95%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Ligand's (LGND) Q4 Sales & Earnings Top, View Raised, Stock Up

by Zacks Equity Research

Ligand Pharmaceuticals (LGND) announces better-than-expected results in fourth-quarter 2022. Stock is up in the after-market hours in response to the news. Management raises 2023 financial outlook.

Earnings Preview: Denali Therapeutics Inc. (DNLI) Q4 Earnings Expected to Decline

by Zacks Equity Research

Denali Therapeutics Inc. (DNLI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Analysts Estimate Travere Therapeutics (TVTX) to Report a Decline in Earnings: What to Look Out for

by Zacks Equity Research

Travere (TVTX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Travere Therapeutics (TVTX) Reports Q3 Loss, Tops Revenue Estimates

by Zacks Equity Research

Travere (TVTX) delivered earnings and revenue surprises of -12.37% and 4.24%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?